SGLT-2 inhibitors for people with type 2 diabetes – Authors' reply
SGLT-2 inhibitors for people with type 2 diabetes – Authors' reply
About this item
Full title
Author / Creator
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
[...]the oral administration of SGLT2i is patient-friendly and the safety profile is, in general, favourable. In terms of more detailed data on the prevention of heart failure, at the American College of Cardiology 2019 Scientific Sessions, we presented and published data showing that dapagliflozin reduces the risk of hospitalisation for heart fail...
Alternative Titles
Full title
SGLT-2 inhibitors for people with type 2 diabetes – Authors' reply
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2275950072
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2275950072
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(19)30699-3
